Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 6 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
42 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
PHARMAVOX from Watermaal-Bosvoorde, company number BE0841606444, closed financial year 2025 with a result of € -323,574 after tax. For that financial year PHARMAVOX recorded a gross margin of € 353,155 and equity of € 6.9 million. Compared with financial year 2024, the result moved from € -220,359 to € -323,574. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 28, 2025.
€ 6.9 million
▼ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -323,574
▼ 47 % more loss than in 2024
Profit after tax over the fiscal year.
€ 99,768
▼ 80% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -2.3 million.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
€ 3,416
▼ 36% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 2.9 million
▼ 7% vs 2024
€ 217,200 is repaid this year. At this pace the long-term loan is gone in ≈ 13 years.
€ 3,038
▼ 79% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 483
▼ 65% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 336,332 | € 343,727 | € 429,765 | € 353,155 | ▼ 18% |
| Profit after taxes | € -235,527 | € -331,487 | € -220,359 | € -323,574 | ▼ € 103,215 |
| Equity | € 7,756,132 | € 7,424,645 | € 7,204,285 | € 6,880,711 | ▼ 4% |
| Total debts | € 5,841,220 | € 5,685,578 | € 5,529,805 | € 4,379,441 | ▼ 21% |
| Cash | € 604,395 | € 543,181 | € 510,510 | € 99,768 | ▼ 80% |
| Land & buildings | € 11,713,333 | € 11,274,113 | € 10,836,892 | € 10,402,115 | ▼ 4% |
| Retained profit | € -1,453,868 | € -1,785,355 | € -2,005,715 | € -2,329,289 | ▼ € 323,574 |
| Bank debt | € 3,565,600 | € 3,348,400 | € 3,131,200 | € 2,914,000 | ▼ 7% |
| Balance sheet total | € 13,597,352 | € 13,110,222 | € 12,734,090 | € 11,260,152 | ▼ 12% |
Key figures of PHARMAVOX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.
What happened to PHARMAVOX?
What happened at PHARMAVOX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 323,574. Source: NBB ↗
- BYJULIET SRL became a director. NBB
- BILIVIT SRL became a director. NBB
- Alfred BOURELY became a director. NBB
- Camille BOURELY became a director. NBB
- Gabrielle BOURELY became a director. NBB
- ALBYORIX SRL became a director. NBB
- Michel BOURELY became a director. NBB
In short
From € 235,527 loss in 2022 to € 323,574 loss in 2025.
A new publication or filing at PHARMAVOX? We notify you, reason included.
Follow PHARMAVOXDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARMAVOX are BYJULIET SRL, BILIVIT SRL, Alfred BOURELY, Camille BOURELY, Gabrielle BOURELY and ALBYORIX SRL.
Directors
According to the 2025 annual accounts
Director · represented by BOURELY JULIET
since 2019
Director · represented by BOURELY CAMILLE
since 2019
Alfred BOURELY
Director
since 2019
Camille BOURELY
Director
since 2019
since 2019
Director · represented by BOURELY ALFRED
since 2019
Director · represented by BOURELY GABRIELLE
since 2019
Juliet BOURELY
Director
since 2019
Establishments
Establishment units
Physical locations of this company
Terhulpsesteenweg 178 box 5
1170 Watermaal-Bosvoorde
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 42 companies are registered at this address.
All companies at this address →Anc. Ets. F. Verdeyen
TAX CONSULT
€ 651,315 gross margin · 2025
CMS DeBacker
€ 27.5 million revenue · 2025
MNG-MANGO BELGIQUE
€ 35 million revenue · 2025
BRUNO DUQUESNE
€ 182,007 gross margin · 2025
+37 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0841.606.444
- VAT number
- BE 0841.606.444
- Registered office
- Terhulpsesteenweg 178 bus 5, 1170 Watermaal-Bosvoorde
- Names & denominations
- PHARMAVOX
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 December 2011
- Peppol
- Active · Active since 17 Jul 2025
- Activities · NACE
Overige zakelijke dienstverlening, neg
Activiteiten van holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Holdings